Low T vs. insufficient T in women: what the evidence says

What did @medhealth360 actually say?

The creator's central argument is that "normal" testosterone levels in women aren't always "optimal" ones. She's pitching the idea that symptoms like low libido, poor sleep, anxiety, and low energy can be treated by pushing testosterone above the normal reference range, even if labs look fine. She also claims testosterone drives apoptosis, killing off "old bad cells" and potentially preventing tumor growth. The framing is sympathetic: aging shouldn't mean feeling worse, and hormones might be why you do.

Does the science back this up?

Partially, and the caveats matter a lot. The concept of "normal vs. optimal" testosterone in women is a real clinical debate, but it's not settled science. The Endocrine Society's 2014 guidelines (Wierman et al., Journal of Clinical Endocrinology and Metabolism) explicitly state there is insufficient evidence to recommend testosterone therapy for women outside of hypoactive sexual desire disorder. That's a narrow indication. The creator is describing a much broader wellness application that regulatory bodies haven't endorsed.

On testosterone and mood, there is some supporting data. Davis et al. (2019, The Lancet Diabetes and Endocrinology) found modest benefits for sexual function and some wellbeing measures in postmenopausal women. But anxiety reduction from supraphysiologic testosterone? The evidence there is thin and inconsistent. Some studies show higher androgens actually correlate with increased anxiety in certain populations.

The apoptosis claim is the most scientifically stretched part of this video. Testosterone does interact with apoptotic pathways, but saying it kills off "old bad cells" and prevents tumors is an oversimplification that borders on misleading.

What did they get wrong (or right)?

Credit where it's due: the creator is correct that reference ranges for female testosterone are based on population averages, not functional thresholds. Symptoms can exist at levels labs call normal. That's a legitimate clinical nuance that many clinicians overlook.

But the apoptosis-and-tumors segment is where the video goes off the rails. She implies that adequate testosterone prevents tumor growth because it promotes cell death. This reverses how some cancers actually work. Testosterone can stimulate androgen-receptor-positive tumors. Breast cancer research is complicated here, but Michels et al. (2020, JAMA Oncology) found higher androgen levels associated with increased breast cancer risk in postmenopausal women. Presenting testosterone as a cellular cleanup crew without that context is irresponsible.

Her comment that elevating testosterone "higher than what's considered normal" is fine because it makes you feel better is also a red flag. Supraphysiologic androgen use in women carries real risks: polycythemia, clitoral hypertrophy, voice changes, and cardiovascular strain. None of that is mentioned.

What should you actually know?

Testosterone therapy for women is a real, evidence-supported option for specific indications, chiefly hypoactive sexual desire disorder, but it is not approved by the FDA for women in the United States in any commercial form. Clinicians who prescribe it off-label or via compounded preparations are working outside formal approval, which isn't automatically wrong, but it does mean the safety and efficacy data are thinner than the video implies.

The "normal isn't optimal" framing is seductive, but it can justify almost any hormone intervention. Reference ranges exist because outcomes data were built around them. Going above range means less data, more uncertainty, and real side effect risk. If you're considering testosterone therapy, the conversation should include lab monitoring, baseline cardiovascular risk, and a frank discussion about what the evidence actually shows for your specific symptoms. A symptom list that matches your 20-year-old self is not a clinical diagnosis.

• The FDA has not approved any testosterone product for women in the U.S.
• Off-label prescribing is legal but means less regulatory oversight of safety data.
• Supraphysiologic testosterone in women carries documented risks including cardiovascular and androgenic side effects.
• Apoptosis is a real cellular process, but testosterone's role in tumor prevention is not established and may run in the opposite direction for some cancers.